PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40640198,Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvants.,2025,"Kirill Vasilev, Irene Hoxie, Eduard Puente-Massaguer, Joshua Yueh, Disha Bhavsar, Maya Singh, Corey P Mallett, Joseph Zimmermann, Florian Krammer","GSK, Rockville, MD, USA.; Inspirevax Inc., Kirkland, Quebec, Canada.",florian.krammer@mssm.edu
40639387,"Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.",2025,"Spyros Chalkias, Patrick Dennis, Dena Petersen, Krishnakumar Radhakrishnan, Leroy Vaughan, Reem Handforth, Alexandra Rossi, Rahnuma Wahid, Darin K Edwards, Jing Feng, Weiping Deng, Honghong Zhou, Elizabeth De Windt, Veronica Urdaneta, Yamuna Paila, Bethany Girard, Saul N Faust, Stephen R Walsh, Catherine A Cosgrove, Jacqueline Miller, Rituparna Das","Moderna, Cambridge, MA, USA. Electronic address: Spyros.Chalkias@Modernatx.com.; Moderna, Cambridge, MA, USA.",Spyros.Chalkias@Modernatx.com
40623115,Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials.,2025,"Kirk U Knowlton, Lianne K Siegel, Christina E Barkauskas, Sanjay Bhagani, Nila J Dharan, Edward M Gardner, Robert L Gottlieb, Marie Helleberg, Helene C Highbarger, Thomas L Holland, Christian Kjer Heerfordt, Susana Lazarte, Lindsey M Leither, Joseph Lutaakome, Magdalena Ardelt, Eleftherios Mylonakis, Sean W X Ong, J Scott Overcash, Hassan Taha, Phyllis C Tien, Barbara W Trautner, David Vallee, Amy C Weintrob, Giota Touloumi, Abdel Babiker","Ralph H Johnson VA Medical Center, Charleston, South Carolina, United States of America.",N/A
40600480,Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.,2025,"Katherine L Nelson, Tammeka Evans Cooper, Yolanda Lawson, Dylan Baker, Satish Mocherla, Megan Dieterich, Theo Hodge, Alftan Dyson, Denise Sutherland-Philips, Heidi Swygard, Lisa Petty, Peter Jeffery, Kenneth Sutton, Courtney Peasant Bonner, Sara M Andrews, Samantha Chang, Piotr Budnik, Kimberly Smith, Annemiek de Ruiter, Maggie Czarnogorski, Nanlesta Pilgrim","GSK, London, UK.",N/A
40592258,Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19.,2025,"Mary Lynn Baniecki, Shunjie Guan, Devendra K Rai, Qingyi Yang, Jonathan T Lee, Li Hao, Edward Weinstein, Craig Hyde, Rhonda D Cardin, Holly Soares, Jennifer Hammond","Pfizer Research and Development, 66 Hudson Blvd, New York, NY, 10001, USA.; Pfizer Research and Development, 1 Portland St, Cambridge, MA, 02139, USA. Electronic address: mary.baniecki@pfizer.com.; Pfizer Research and Development, 1 Portland St, Cambridge, MA, 02139, USA.; Pfizer Research and Development, 1 Portland St, Cambridge, MA, 02139, USA. Electronic address: Shunjie.Guan@pfizer.com.; Pfizer Research and Development, 401 N Middletown Rd, Pearl River, NY, 10965, USA.; Pfizer Research and Development, 280 Shennecossett Rd, Groton, CT, 06340, USA.",mary.baniecki@pfizer.com
40591130,Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.,2025,"Oyeniyi Diya, Juleen Gayed, Francine S Lowry, Hua Ma, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Mark Cutler, Todd Belanger, David Cooper, Xia Xu, Robin Mogg, Özlem Türeci, Uǧur Şahin, Kena A Swanson, Kayvon Modjarrad, Annaliesa S Anderson, Alejandra Gurtman, Nicholas Kitchin","Vaccine Research and Development, Pfizer Ltd, Marlow, UK.; Vaccine Research and Development, Pfizer Ltd, Marlow, UK. juleen.gayed@pfizer.com.; BioNTech, Mainz, Germany.; Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.",juleen.gayed@pfizer.com
